A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stabl
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
| Condition(s) | Type 2 Diabetes |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months. |
| Who can participate | Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incretins for at least three months prior to screening: * Injectable semaglutide (1 and 2 milligram (mg)) * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg) Exclusion Criteria: * Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma * Have a prior or planned surgical treatment for obesity * Have any of the following cardiovascular conditions within three months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstabl |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Eli Lilly and Company |
| Locations | Phoenix, Arizona, United States; Santa Ana, California, United States; Ocala, Florida, United States; Oviedo, Florida, United States; Lawrenceville, Georgia, United States; Lawrenceville, Georgia, United States (+54 more sites) |
| Start date | 2025-03-28 |
| NCT ID | NCT06897475 |
| Official listing | https://clinicaltrials.gov/study/NCT06897475 |